Revisions To Japan Pharmaceutical Affairs Law On The Table For Internal Watchdog Agency
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Revisions to Japan's Pharmaceutical Affairs Law are likely to focus on the establishment of a watchdog agency to monitor the Ministry of Health, Labor and Welfare and the legal structure of drug package inserts
You may also be interested in...
MHLW Relied On EU and U.S. For Actos Safety Data, But Newly Funded Health Records Database Will Boost Japan's Pharmacovigilance
TOKYO - Japan's Ministry of Health, Labor and Welfare followed the lead of EMA and U.S. FDA and requested Takeda Pharmaceutical Co. Ltd. to change labeling for Actos (pioglitazone) to reflect safety concerns about the risk of bladder cancer. MHLW had to rely on epidemiological data compiled by EMA, but MHLW's safety division hopes new funding from the government will help build an electronic health records database to conduct similar pharmacovigilance epidemiology studies for the Japanese market
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).